Indi Molecular is developing protein catalyzed capture (PCC) agents as a small synthetic molecule replacement for antibody-based therapeutics. PCCs are poised to play a central role in therapy given their ability to be deployed as both a precision in vivo PET diagnostic and as a targeted therapeutic. For radiotherapy this dual role is accomplished by choice of the complexed radionuclide sharing the same chelation chemistry. Chemotherapy can similarly be specifically delivered to diseased cells by the protein catalyzed capture technology.
The company launched in 2013 with a $1.8 million seed round, followed by an $11.5 million Series A in 2017.
The company launched in 2013 with a $1.8 million seed round, followed by an $11.5 million Series A in 2017.
Total raised: $60.55M
Founded date: 2013
Investors 3
| Date | Name | Website |
| 08.11.2022 | M Ventures | m-ventures... |
| - | Asset Mana... | assetman.c... |
| - | InterWest ... | interwest.... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 07.07.2017 | Series A | $11.5M | - |
| 29.04.2014 | - | $47.25M | - |
| 10.12.2013 | Seed | $300K | - |
| 20.09.2013 | Seed | $1.5M | - |
Mentions in press and media 9
| Date | Title | Description |
| 12.07.2017 | Indi Molecular Raises $11.5M in Series A Funding | Indi Molecular, a Culver City, CA-based life sciences company, raised $11.5M in Series A funding. The round was led by M Ventures; Legend Capital; Sabey Corporation; and existing investors including Asset Management Ventures. As part of the... |
| 07.07.2017 | Indi Molecular Raises $11.5M | Culver City-based Indi Molecular, a developer of protein catalyzed capture agent (PCC) biotechnology being aimed in research tools, diagnostic agents, and PET imaging, has raised $11.5M in a Series A funding. The funding was led by M Ventur... |
| 29.06.2017 | Term Sheet — Thursday, June 29 | New Money, Old Deals, Lingering Questions LA Tech: Upfront Ventures has closed its fourth core fund with $400 million in commitments. It’s the firm’s largest ever, and according to managing partner Mark Suster, the largest Los Angeles-based... |
| 29.06.2017 | Indi Molecular Grabs $11.5M | CULVER CITY, CA, Indi Molecular announced today that it has raised a $11.5 million Series-A financing. >> Click here for more funding data on Indi Molecular >> To export Indi Molecular funding data to PDF and Excel, click he... |
| 29.04.2014 | Indi Raises $47.25M | Indi (Integrated Diagnostics), a Seattle, WA-based molecular diagnostics company pioneering the use of blood-based proteomic tests, raised $47.25m in funding. It came from the $30.25m closing of its Series B round and $17m in non-dilutive d... |
| 10.12.2013 | Indi Molecular Picks Up $300K More In $1.8M Seed Funding | Culver City-based Indi Molecular, a developer of synthetic replacements for antibodies, announced Tuesday that it has raised $300,000 more in its seed funding, bringing the total raised in the round to $1.8M. The new funding was led by Inte... |
| 23.09.2013 | Indi Molecular Raises $1.5M For Antibody Startup | Culver City- and Seattle-based Indi Molecular, a startup developing a synthetic replacement for antibodies, has raised $1.5M in a seed funding round. The funding was led by InterWest Partners, and also included a number of un-named angel in... |
| 20.09.2013 | Indi Molecular Raises $1.5M Seed Round | CULVER CITY, CA, Indi Molecular, which pioneered a synthetic replacement for antibodies, today announced that it has raised a $1.5 million seed round led by InterWest Partners. >> Click here for more funding data on Indi Molecular ... |
| 20.09.2013 | Indi Molecular Raises $1.5M in Seed Funding | Indi Molecular, a Culver City, CA-based developer of a synthetic replacement for antibodies, raised $1.5m in seed funding. The round was led by InterWest Partners, with participation from several angel investors. The company intends to use ... |